China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a leading provider of marketing, promotion and sales services for prescription drugs in China. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007. The group successfully listed on the Main Board of Hong Kong Stock Exchange on 28 September 2010 (Stock code: 867), on the same day the company canceled the trading of its shares on AIM in London. CMS has the largest third-party promotion network in China in terms of hospital coverage, therapeutic focus and number of sales people. As of 31 December 2010, CMS has over 970 staff in its marketing, promotion and sales team, reaches over 7,100 hospitals located across 31 provinces and over 120,000 target physicians in China, and at the present, CMS is marketing 9 main products in China which cover several therapeutic areas including the neurology, psychiatry, hepatology, gastroenterology, infectious diseases, urology, ophthalmology, cardiovascular disease, pediatrics and oncology. With deep insight and understanding of the Chinese pharmaceutical market, available treatment options, patient demography and potential competitive advantages of drugs, CMS will continue to focus on new product introduction and expand its sales network to consolidate and promote its leading position in the pharmaceutical services market in China. In June 2009, the Company acquired 24.49% interest in Ophol Limited.